Effect of tumor length on clinical stage for non-operative esophageal squamous cell carcinoma patients—multicenter retrospective data analysis (3JECROG R-01D)
Zhou Zhiguo1, Wang Xin2, Wang Lan1, Chen Junqiang3, Zhang Wencheng4, Wang Xiaomin5, Ge Xiaolin6, Shen Wenbin1, Hu Miaomiao7, Yuan Qianqian7, Xu Yonggang8, Hao Chongli7, Qie Shuai9, Lu Na10, Pang Qingsong4, Wang Ping4, Zhao Yidian5, Sun Xinchen6, Zhang Kaixian7, Li Gaofeng8, Li Ling7, Liu Miaoling9, Wang Yadi10, Li Chen2, Zhu Shuchai1, Xiao Zefen2, Han Chun1, Qiao Xueying1
1Department of Radiation Oncology,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China; 2Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences ( CAMS ) and Peking Union Medical College (PUMC),Beijing 100021,China; 3Department of Radiation Oncology,Fujian Cancer Hospital/Fujian Medical University Cancer Hospital,Fuzhou 350014,China; 4Department of Radiation Oncology,Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer,Tianjin 300060,China; 5Department of Radiation Oncology,Anyang Cancer Hospital,Anyang 455000,China; 6Department of Radiation Oncology,First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China; 7Department of Oncology,Tengzhou Central People′s Hospital,Tengzhou 277599,China; 8Department of Radiation Oncology,Beijing Hospital,National Center of Gerontology,Beijing 100730,China; 9Department of Radiation Oncology,Affiliated Hospital of Hebei University,Baoding 071000,China; 10Department of Radiation Oncology,PLA Army General Hospital,Beijing 100700,China
Abstract：Objective To retrospectively analyze the effect of tumor length on the prognosis in stage Ⅱ/Ⅲ esophageal squamous cell carcinoma (ESCC) patients treated with definitive radiotherapy and to evaluate the role of tumor length in clinical stage for non-operative ESCC patients. Methods The data of 2 086 ESCC patients who were treated with definitive radiotherapy from 2002 to 2016 in 10 hospitals (3JECROG) were analyzed. The effect of tumor length on overall survival (OS) was analyzed and stratified analysis of tumor length was done in different stages of ESCC. Results The median OS and median progression-free survival (PFS) time of the whole group were 25.6 months and 18.2 months respectively. The Cox multivariate analysis showed that treatment mode,age,clinical stage and tumor length were independent prognostic factors. The median,1-,3-,and 5-year OS were 28.9 months,77.3%,45.0%,and 36.3% versus 21.9 months,69.9%,37.9%,and 28.1% for patients with ≤5 cm and patients>5 cm respectively (P<0.05). For stage Ⅱ patients,the median OS were 42.1 and 38.9 months respectively in ≤5 cm group and>5 cm group (P=0.303). And for stage Ⅲ patients,the median OS were 23.9 and 19.3 months respectively in ≤5 cm group and>5 cm group (P<0.001). The median OS with N1was 24.1 and 18.4 months,respectively in≤5 cm group and>5 cm group (P<0.001). Conclusions The tumor length was an independent prognostic factor for stage Ⅱ/Ⅲ patients treated definitive radiotherapy. The tumor length may be helpful in clinical staging of ESCC,especially for stage Ⅲ and N1.
Zhou Zhiguo,Wang Xin,Wang Lan et al. Effect of tumor length on clinical stage for non-operative esophageal squamous cell carcinoma patients—multicenter retrospective data analysis (3JECROG R-01D)[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 490-494.
[1]Eloubeidi MA,Desmond R,Arguedas MR,et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U. S.:the importance of tumor length and lymph node status[J]. Cancer,2002,95(7):1434-1443. DOI:10.1002/cncr.10868. [2]Griffiths EA,Brummell Z,Gorthi G,et al. Tumor length as a prognostic factor in esophageal malignancy:univariate and multivariate survival analyses[J]. J Surg Oncol,2006,93(4):258-267. DOI:10.1002/jso.20449. [3]Wu N,Pang LW,Chen ZM,et al. Tumour length is an independent prognostic factor of esophageal squamous cell carcinomas[J]. Chin Med J,2012,125(24):4445-4448. DOI:10.3760/cma.j.issn.0366-6999.2012.24.022. [4]Wang BY,Liu CY,Lin CH,et al. Endoscopic tumor length is an independent prognostic factor in esophageal squamous cell carcinoma[J]. Ann Surg Oncol,2012,19(7):2149-2158. DOI:10.1245/s10434-012-2273-y. [5]邵明雯,陈亮,李红霞,等. 病变长度对淋巴结阴性食管癌患者的临床病理及预后影响[J]. 中国癌症杂志,2014(11):846-851. DOI:10.3969/j.issn.1007-3969.2014.11.008. Shao MW,Chen L,Li HX,et al. Clinical pathology and prognosis of lesion length in patients with lymph node negative esophageal carcinoma[J]. Chin Oncol,2014(11):846-851. DOI:10.3969/j.issn.1007-3969.2014.11.008. [6]中国非手术治疗食管癌临床分期专家小组. 非手术治疗食管癌的临床分期标准(草案)[J]. 中华放射肿瘤学杂志,2010,19(3):179-180. DOI:10.3760/cma.j.issn.1004-4221.2010.03.001.Expert Group on clinical staging of non-surgical treatment of esophageal cancer in China. Clinical staging criteria for non-surgical treatment of esophageal cancer (draft)[J]. Chin J Radiat Oncol,2010,19(3):179-180. DOI:10.3760/cma.j.issn.1004-4221.2010.03.001. [7]Bollschweiler E,Baldus SE,Schroder W,et al. Staging of esophageal carcinoma:length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?[J]. J Surg Oncol,2006,94(5):355-363. DOI:10.1002/jso.20569. [8]王鑫,王澜,陈俊强,等. 多中心食管鳞癌根治性三维放疗的预后分析——3JECROG R-01[J]. 中华放射肿瘤学杂志,2018,27(11):959-964. DOI:10.3760/cma.j.issn.1004-4221.2018.11.002. Wang X,Wang L,Chen JQ,et al. Prognostic analysis of radical three-dimensional radiotherapy for multi-center esophageal squamous cell carcinoma—3JECROG R-01[J]. Chin J Radiat Oncol,2018,27(11):959-964. DOI:10.3760/cma.j.issn.1004-4221.2018.11.002. [9]Beahrs OH,Myers MH. American joint committee on cancer manual for staging of cancer[M].2nd ed. Philadelphia:JB Lippincott,1983:219-226. [10]Bolton WD,Hofstetter WL,Francis AM,et al. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma[J]. J Thorac Cardiovasc Surg,2009,138(4):831-836. DOI:10.1016/j.jtcvs.2009.02.003. [11]Ma MQ,Yu ZT,Tang P,et al. Is tumor length a prognostic indicator for esophageal squamous cell carcinoma? A single larger study among Chinese patients[J]. Int J Clin Exper Pathol,2015,8(5):5008-5016. [12]Feng JF,Huang Y,Zhao Q. Tumor length in elderly patients with esophageal squamous cell carcinoma:is it a prognostic factor?[J]. Up J Med Sci,2013,118(3):145-152. DOI:10.3109/03009734.2013.792887. [13]Umezawa R,Jingu K,Matsushita H,et al. Long-term results of chemoradiotherapy for stage Ⅱ-Ⅲ thoracic esophageal cancer in a single institution after 2000-with a focus on comparison of three protocols[J]. BMC Cancer,2015,15(4):813-821. DOI:10.1186/s12885-015-1836-2. [14]Berry MF. Esophageal cancer:staging system and guidelines for staging and treatment[J]. J Thorac Dis,2014,6 Suppl 3:S289-297. DOI:10.3978/j.issn.2072-1439.2014.03.11. [15]Yendamuri S,Swisher SG,Correa AM,et al. Esophageal tumor length is independently associated with long-term survival[J]. Cancer,2009,115(3):508-516. DOI:10.1002/cncr.24062. [16]Mirinezhad SK,Jangjoo AG,Seyednejad F,et al. Impact of tumor length on survival for patients with resected esophageal cancer[J]. As Pac J Cancer Prevent,2014,15(2):691-694. DOI:10.7314/APJCP.2014.15.2.691. [17]Yin H,Li D,Zhu C,et al. Factors relevant to the prognosis of patients with esophageal cancer who received intensity-modulated radiotherapy[J]. Thorac Cancer,2018,9(10):1215-1219. DOI:10.1111/1759-7714.12800. [18]苏娜,王雅棣,李成林,等. N0期胸段食管癌GTV长度和最大直径及体积对放疗预后影响[J]. 中华放射肿瘤学杂志,2014,23(1):27-30. DOI:10.3760/cma.j.issn.1004-4221.2014.01.007. Su N,Wang YD,Li CL,et al. Effect of GTV length and maximum diameter and volume of N0 thoracic esophageal carcinoma on radiotherapy prognosis[J]. Chin J Radiat Oncol,2014,23(1):27-30. DOI:10.3760/cma.j.issn.1004-4221.2014.01.007. [19]Rice TW,Zuccaro GJ,Adelstein DJ,et al. Esophageal carcinoma:depth of tumor invasion is predictive of regional lymph node status[J]. Ann Thorac Surg,1998,65(3):787-792. DOI:10.1016/S0003-4975(97)01387-8. [20]Rice TW,Ishwaran H,Hofstetter WL,et al. Esophageal cancer:associations with (pN+) lymph node metastases[J]. Ann Surg,2017,265(1):122-129. DOI:10.1097/SLA.0000000000001594.
2019, Vol. 28 
